These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18279794)

  • 1. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs.
    Davda JP; Jain M; Batra SK; Gwilt PR; Robinson DH
    Int Immunopharmacol; 2008 Mar; 8(3):401-13. PubMed ID: 18279794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
    Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
    Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
    Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
    Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.
    Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK
    J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
    Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
    Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors.
    Jain M; Chauhan SC; Singh AP; Venkatraman G; Colcher D; Batra SK
    Cancer Res; 2005 Sep; 65(17):7840-6. PubMed ID: 16140953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments.
    Ferl GZ; Kenanova V; Wu AM; DiStefano JJ
    Mol Cancer Ther; 2006 Jun; 5(6):1550-8. PubMed ID: 16818514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting.
    Pavlinkova G; Batra SK; Colcher D; Booth BJ; Baranowska-Kortylewicz J
    Peptides; 2003 Mar; 24(3):353-62. PubMed ID: 12732332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
    Garg A; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
    J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody.
    Beresford GW; Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Int J Cancer; 1999 Jun; 81(6):911-7. PubMed ID: 10362138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.
    Baxter LT; Zhu H; Mackensen DG; Jain RK
    Cancer Res; 1994 Mar; 54(6):1517-28. PubMed ID: 8137258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
    Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
    Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.